Draft Provider-Administered Drug Policies (Excluding Oncology) - Blue Advantage

To ensure that the development of Blue Cross and Blue Shield of Alabama provider-administered drug policies occurs through an open, collaborative process, we invite physicians and other providers to submit comments about pharmacy policies that are in the draft stage.

Draft Policies

Draft provider-administered drug policies (excluding oncology drugs) are listed below in alphabetical order. If there are no policies listed, then no policies are currently in draft status.

How to Submit Comments

We invite our participating physicians and other providers to submit scientific, evidence-based information, professional consensus opinions and other information supported by medical literature relevant to these draft policies for consideration. We receive comments for 45 days from the posting date listed on the document.

Participating providers can comment on draft policies two ways:

Fax: 205-733-6471

 

Note: Coverage is subject to member's specific benefits. Group-specific policies will supersede these policies when applicable. Please refer to member's benefit plan.

 

 

 


 

 

 

 

 

 

Policy # Policy Title Print View
PH-90347 Fasenra® (benralizumab)